KT-1002
/ Koutif Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 20, 2019
Newly added product
(Businesswire)
- Preclinical, Inflammatory Bowel Disease, Rheumatoid Arthritis
Pipeline update
February 20, 2019
Koutif Therapeutics announces FDA acceptance of IND application for novel new treatment of IBD
(Businesswire)
- "Koutif Therapeutics today announced that its investigational new drug (IND) application for KT-1002 has been cleared by the US Food and Drug Administration to begin a Phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s Disease."
IND
1 to 2
Of
2
Go to page
1